Moxifloxacin activity against clinical isolates compared with the activity of ciprofloxacin

International Journal of Antimicrobial Agents

Volumn 20, Issue 3, 2002, Pages 196-200

  Aktaş, Zerrin ^a   Gönüllü, Nevriye ^b   Şalcioǧlu, Melek ^a   Bal, Çiǧdem ^a   Anǧ, Özdem ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Fluoroquinolones; MIC; Moxifloxacin

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; MOXIFLOXACIN; QUINOLONE DERIVATIVE;

ACINETOBACTER; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG ACTIVITY; ENTEROBACTER; ENTEROCOCCUS; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; KLEBSIELLA PNEUMONIAE; MORAXELLA CATARRHALIS; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; PSEUDOMONAS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; QUINOLINES;

EID: 0036711441     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(02)00174-7     Document Type: Article

References (21)

1. Hooper D.C. New uses for new and old quinolones and the challenge of resistance. Clin. Infect. Dis. 30:2000;243-254.
2. Schedletzky H., Wiedemann B., Heisig P. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus. J. Antimicrob. Chemother. 43:1999;31-37.
3. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4. NCCLS, Wayne, PA, 2000.
4. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. 12th informational supplement M100-S12. NCCLS, Wayne, Pa, 2002.
5. Andrews J.M., Ashby J.P., Jevons G.M., Wise R. Tentative minimum inhibitory concentration and zone diameter breakpoints for moxifloxacin using BSAC criteria. J. Antimicrob. Chemother. 44:1999;819-822.
6. Hooper D.C. Emerging mechanisms of fluoroquinolone resistance. Emerging Infect. Dis. 7:2001;337-341.
7. Jones M.E., Staples A.M., Critchley I., et al. Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States. Antimicrob. Agents Chemother. 44:2000;2645-2652.
8. Jones M.E., Visser M.R., Klootwijk M., Heisig P., Verhoef J., Schmitz F.J. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linezolid, quinupristin-dalfopristin, gentamisin, and vancomycin against clinical isolates of ciprofloxacin-resistant and-susceptible Staphylococcus aureus strains. Antimicrob. Agents Chemother. 43:1999;421-423.
9. Woodcock J.M., Andrews J.M., Boswell F.J., Brenwald N.P., Wise R. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob. Agents Chemother. 41:1997;101-106.
10. Pong A., Thomson K.S., Moland E.S., Chartrand S.A., Sanders C.C. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin. J. Antimicrob. Chemother. 44:1999;621-627.
11. Appelbaum P.C., Hunter P.A. The fluoroquinolone antibacterials: past, present and future perspectives. Int. J. Antimicrob. Agents. 16:2000;5-15.
12. Thomson K.S. Minimizing quinolone resistance: are the new agents more or less likely to cause resistance. J. Antimicrob. Chemother. 45:2000;719-723.
13. Garau J., Xercavins M., Rodriguez-Carballeira M., et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob. Agents Chemother. 43:1999;2736-2741.
14. Oethinger M., Conrad S., Kaifel K., et al. Molecular epidemiology of fluoroquinolone-resistant Escherichia coli bloodstream isolates from patients admitted to European cancer centers. Antimicrob. Agents Chemother. 40:1996;387-392.
15. Yücesoy M., Yulug N., Kocagöz S., Ünal S., Çetin S., Çalangu S. Antimicrobial resistance of gram-negative isolates from intensive care units in Turkey: comparison to previous 3 years. J. Chemother. 12:2000;294-298.
16. Heinemann B., Wisplinghoff H., Edmond M., Seifert H. Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains. Antimicrob. Agents Chemother. 44:2000;2211-2213.
17. Fass R.J. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Antimicrob. Agents Chemother. 41:1997;1818-1824.
18. Barman Balfour J.A., Lamb H.M. Moxifloxacin. Drugs. 59:2000;115-139.
19. Sener B., Günalp A. Trends in antimicrobial resistance of Streptococcus pneumoniae in children in a Turkish hospital. J. Antimicrob. Chemother. 42:1998;381-384.
20. Öngen B., Kaygusuz A., Özalp M., Gürler N., Töreci K. Penicillin resistance in Streptococcus pneumoniae in Istanbul, Turkey [letter]. J. Clin. Microbiol. Infect. 1:1995;150.
21. Kanra G., Erdem G., Ceyhan M., Klugman K.P., Vasas A. Serotypes and antibacterial susceptibility of pneumococci isolated from children with infections in Ankara in relation to proposed pneumococcal vaccine coverage. Acta Paediatr. Jpn. 40:1998;437-440.